China's elite don traditional garb for annual 'Two Sessions' talking shop
Sporting military uniforms and multi-coloured traditional garb, delegates from all four corners of China descended on the capital on Tuesday for the country's largest annual political event -- a red-carpet cameo for the ruling elite.
China's "Two Sessions" kick off this week, with thousands of representatives of the country's top consultative political body and its rubber-stamp parliament gathering to talk about everything from economic policy to social issues.
Security was tight around Beijing, with plainclothes police officers and elderly volunteers in red armbands monitoring for anything that could spoil the tightly choreographed conclave.
On nearby Chang'an Avenue, cars trudged along in traffic and pedestrians were stopped for security checks.
Many delegates sported the typical dark suit and tie of career Communist officials.
But that was punctuated with the occasional pop of colour and traditional dress from representatives of China's 55 officially recognised minority groups.
Yang Xiaohua, a delegate from southwestern Yunnan province, was wearing the intricately embroidered dress of her Naxi minority group as she arrived in the stately Great Hall of the People for her third year.
A delegate to the Chinese People's Political Consultative Conference, the middle school teacher said she planned to propose education-related policies.
She said she thought the ruling Communist Party was giving "more and more weight" to delegates' opinions.
"There are surprises every time," she told AFP.
"I think there's not much to say about China's overall direction, we are very satisfied."
"Life has got better and better for ethnic minorities, so we hope the country will prosper and flourish, so that people can work and exist in peace."
- 'Challenges' -
Handfuls of representatives dressed in dark green uniforms of China's military brushed past journalists in the Great Hall.
But other delegates were more keen to chat as they made their way to the assembly room.
Wu Haiying, of northeastern Jilin province, said she hoped to work with the party to provide women with a better "childbearing environment".
But she acknowledged the country was facing difficulties -- particularly in the economy.
"But even so, in the process of national development and progress, we will still experience challenges – in economic development, individual development, career development," she said.
Attending the two sessions as a CPPCC representative for the third year, Wu said "the feeling of seeing old friends is very good".
Outside the theatre-like assembly room was an elaborate floral display in different shades of pink, with pots around the hall.
- Optimistic delegates -
Inside, delegates including President Xi Jinping and his top brass stood to sing a rendition of China's national anthem.
Tuesday's CPPCC was low-stakes compared to the almost simultaneous gathering of China's legislature, the National People's Congress (NPC), which starts on Wednesday.
That meeting is widely expected to see Beijing hash out plans for a response to the many economic headwinds China is facing, from trade war threats abroad to sluggish consumption and a proper crisis at home.
Delegates, unsurprisingly, put on an optimistic face when asked for comment by journalists.
"I believe that in dealing with global and domestic economic development, China's economy will escape this puzzle," Ruan Hongxian, from southwestern Yunnan province, told AFP.
"And I believe that China's economy will be even better developed in the future."
mya-oho/je/dhw
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Opinion - Trump shouldn't import socialist price controls
Remember when Republican presidential candidate Donald Trump castigated 'Comrade Kamala' Harris, then the Democratic nominee, for supporting price controls? It wasn't that long ago — just last August. At a campaign rally in Pennsylvania, Trump told the crowd: 'In her speech yesterday, Kamala went full Communist … She wants to destroy our country. After causing catastrophic inflation, Comrade Kamala announced that she wants to institute socialist price controls.' Harris's price controls were largely aimed at food in grocery stores, though she also frequently touted the 2022 Inflation Reduction Act's backdoor price controls — under the guise of 'negotiations' — on a certain number of expensive drugs. Trump was right to criticize Harris for supporting price controls on food, as well as prescription drugs. And, given the election results, it seems the public agreed with him. Price controls are the progressive left's go-to solution for almost all economic problems. But price controls virtually always lead to unintended consequences: shortages of the price-controlled products or services; lower quality as manufacturers cut corners to meet government-imposed price points; less innovation, since companies don't know if they'll be allowed to recover their costs; and a black market where people pay more to get what they want or need. So it's puzzling to see Trump now proposing a version of drug price controls himself. It's not the first time, either. During his first term, Trump pushed for 'drug importation,' encouraging U.S. citizens to buy medicines from countries like Canada — even though the FDA has warned those drugs could be fake or substandard. The effort fizzled, and even Florida, which tried a state-level importation scheme, eventually abandoned its program. Trump's latest idea is called 'Most Favored Nation' pricing. Details are thin, but a recent executive order says, 'To the extent consistent with law, the Secretary of Health and Human Services (Secretary) shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price.' That 'most-favored' country will almost certainly be one with government-run health care — that is, socialized medicine. These systems are known for price controls, which lead to shortages, long wait times, and limited access to cutting-edge treatments. The goal of Most Favored Nation is to lower prices on expensive drugs. Americans do pay more for brand-name drugs than patients elsewhere. But they also pay less for generics, which account for roughly 90 percent of all prescriptions. One reason for the disparity is the middlemen in our system, known as pharmacy benefit managers. Their job is to negotiate lower prices with drugmakers. But those savings often don't make it to patients. Instead, pharmacy benefit managers keep a big chunk for themselves — on average, $0.42 of every $1 spent on brand-name drugs in the commercial market, by one estimate. In many cases, those pharmacy benefit manager cuts are larger than the total price of the drug in Europe. It's clear our system could work better. 'Shark Tank' entrepreneur Mark Cuban launched the Cost Plus Drug Company in 2022 to bypass these middlemen. The Cost Plus website says, 'Our prices are the true cost to get each medication from the manufacturer to you. We cut out the pharmacy middlemen and negotiate directly with manufacturers to get the best possible price.' The company tacks on 15 percent for overhead and a $5 filling fee. While customers may not save much on some widely used generics, the discounted prices on more expensive brand name and generic drugs are significantly lower than what most people would experience at their local pharmacy. Cost Plus has hundreds of drugs for nearly 100 listed medical conditions, and it's looking to add new drugs all the time. It's only been in business a few years and is working to expand. We also shouldn't ignore the fact that Americans are subsidizing below-market prices abroad. The United States funds a disproportionate share of global pharmaceutical innovation, while other wealthy nations impose price caps and benefit from our investment. If Trump wants to stop other countries from taking advantage of us, he should take the approach he's using to get countries to pay more for defense. Cuban's Cost Plus experiment proves we don't need Most Favored Nation pricing. Let socialized systems keep their socialized prices, limited access and denial of care. Tweaking a line Trump likes to use and applying it to prescription drugs: We don't need a new law. We just don't need a middleman. Merrill Matthews is a public policy and political analyst and the co-author of 'On the Edge: America Faces the Entitlements Cliff.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
The Hill
5 hours ago
- The Hill
Trump shouldn't import socialist price controls
Remember when Republican presidential candidate Donald Trump castigated 'Comrade Kamala' Harris, then the Democratic nominee, for supporting price controls? It wasn't that long ago — just last August. At a campaign rally in Pennsylvania, Trump told the crowd: 'In her speech yesterday, Kamala went full Communist … She wants to destroy our country. After causing catastrophic inflation, Comrade Kamala announced that she wants to institute socialist price controls.' Harris's price controls were largely aimed at food in grocery stores, though she also frequently touted the 2022 Inflation Reduction Act's backdoor price controls — under the guise of 'negotiations' — on a certain number of expensive drugs. Trump was right to criticize Harris for supporting price controls on food, as well as prescription drugs. And, given the election results, it seems the public agreed with him. Price controls are the progressive left's go-to solution for almost all economic problems. But price controls virtually always lead to unintended consequences: shortages of the price-controlled products or services; lower quality as manufacturers cut corners to meet government-imposed price points; less innovation, since companies don't know if they'll be allowed to recover their costs; and a black market where people pay more to get what they want or need. So it's puzzling to see Trump now proposing a version of drug price controls himself. It's not the first time, either. During his first term, Trump pushed for 'drug importation,' encouraging U.S. citizens to buy medicines from countries like Canada — even though the FDA has warned those drugs could be fake or substandard. The effort fizzled, and even Florida, which tried a state-level importation scheme, eventually abandoned its program. Trump's latest idea is called 'Most Favored Nation' pricing. Details are thin, but a recent executive order says, 'To the extent consistent with law, the Secretary of Health and Human Services (Secretary) shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price.' That 'most-favored' country will almost certainly be one with government-run health care — that is, socialized medicine. These systems are known for price controls, which lead to shortages, long wait times, and limited access to cutting-edge treatments. The goal of Most Favored Nation is to lower prices on expensive drugs. Americans do pay more for brand-name drugs than patients elsewhere. But they also pay less for generics, which account for roughly 90 percent of all prescriptions. One reason for the disparity is the middlemen in our system, known as pharmacy benefit managers. Their job is to negotiate lower prices with drugmakers. But those savings often don't make it to patients. Instead, pharmacy benefit managers keep a big chunk for themselves — on average, $0.42 of every $1 spent on brand-name drugs in the commercial market, by one estimate. In many cases, those pharmacy benefit manager cuts are larger than the total price of the drug in Europe. It's clear our system could work better. 'Shark Tank' entrepreneur Mark Cuban launched the Cost Plus Drug Company in 2022 to bypass these middlemen. The Cost Plus website says, 'Our prices are the true cost to get each medication from the manufacturer to you. We cut out the pharmacy middlemen and negotiate directly with manufacturers to get the best possible price.' The company tacks on 15 percent for overhead and a $5 filling fee. While customers may not save much on some widely used generics, the discounted prices on more expensive brand name and generic drugs are significantly lower than what most people would experience at their local pharmacy. Cost Plus has hundreds of drugs for nearly 100 listed medical conditions, and it's looking to add new drugs all the time. It's only been in business a few years and is working to expand. We also shouldn't ignore the fact that Americans are subsidizing below-market prices abroad. The United States funds a disproportionate share of global pharmaceutical innovation, while other wealthy nations impose price caps and benefit from our investment. If Trump wants to stop other countries from taking advantage of us, he should take the approach he's using to get countries to pay more for defense. Cuban's Cost Plus experiment proves we don't need Most Favored Nation pricing. Let socialized systems keep their socialized prices, limited access and denial of care. Tweaking a line Trump likes to use and applying it to prescription drugs: We don't need a new law. We just don't need a middleman. Merrill Matthews is a public policy and political analyst and the co-author of 'On the Edge: America Faces the Entitlements Cliff.'
CNBC
6 hours ago
- CNBC
In China, fears grow of an EV financial crisis amid pricing war
At a used car market in Beijing, salesman Ma Hui said he fears China's electric vehicle industry is in a race to the bottom. EV makers, led by the country's market leader BYD, have been engaged in a bruising price war, depressing profits for the brands, as well as sellers such as Ma. "All of us were losing money last year," Ma said about his fellow used car sellers in the market. "There are too many companies making too many new energy cars." China's trading partners have often accused the country of flooding the global market with cheap Chinese EVs. These days, similar accusations are flying within China, raising concerns about financial stress in the industry. The official Communist Party paper, the People's Daily, for example, published a commentary on Monday, titled "The 'Price War' In The Automotive Industry Leads Nowhere And Has No Future." "Disorderly 'price wars' squeeze profits across the chain, impacting the entire ecosystem and risking income declines for workers," the paper warned. "Long-term, this 'race to the bottom' competition is unsustainable." BYD is drawing the most fire after it announced price cuts in late May for many of its models. Some of the discounts are as steep as 34%. Its cheapest car, the Seagull mini hatchback, now costs only about $7,700, down from about $10,000. The intense price war has led high-profile auto executives to sound the alarm — with the head of Great Wall Motor calling the industry "unhealthy." In an interview with Chinese news outlet Sina Finance on May 23, chairman Wei Jianjun drew parallels to China's moribund property sector and its now defunct poster child, developer Evergrande. "An 'Evergrande-like' crisis already exists in the automotive industry," he said. "It just hasn't erupted yet." A government-backed industry group has also called on companies not to "dump" vehicles below the cost of production. In a statement, the China Association of Automobile Manufacturers took a veiled swipe at BYD. "A certain automaker has taken the lead in launching significant price cuts and many companies have followed suit, triggering a new round of 'price war' panic," the group said. BYD dismissed Wei's comment as alarmist and said it believes in fair competition in response to CAAM's criticism. In a sign of further strain, sellers at the Beijing used car market told CNBC about a phenomenon known as "zero mileage used cars," which is meant to help auto manufacturers and dealers inflate sales volumes. This happens when cars are registered and plated and then marked as sold, but haven't ever been driven. Ma said he is worried about where the fierce competition leads. He told CNBC he sees the impact of the fierce competition on consumers who are already shy about spending in the down economy. "With the price dropping like this, a lot of buyers might wait," he said.
